367 Results for "

PERK

" in MedChemExpress (MCE) Product Catalog:
Products (367)

367 Results for "PERK" in MCE Product Catalog:

  • Categories Recommended:
    More
166
166 Publications Verification
Cat. No.: HY-10254
CAS No.: 391210-10-9
Purity:  99.95%
Synonyms: PD0325901; PD325901
Target:  

MEK Autophagy Apoptosis

Research Areas:  

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
141
141 Cited Publications
Cat. No.: HY-18072
CAS No.: 1337531-36-8
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM.
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-13820
CAS No.: 1337532-29-2
Purity:  99.66%
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
loading...
    loading...
58
58 Cited Publications
Cat. No.: HY-15816A
CAS No.: 1956366-10-1
Purity:  99.89%
Synonyms: BVD-523 hydrochloride; VRT752271 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
58
58 Cited Publications
Cat. No.: HY-15816
CAS No.: 869886-67-9
Purity:  99.95%
Synonyms: BVD-523; VRT752271
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-12495
CAS No.: 1597403-47-8
Purity:  99.49%
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Neurological Disease

ISRIB (trans-isomer) is a potent inhibitor of PERK with an IC50 of 5 nM. ISRIB potently reverses the effects of eIF2α phosphorylation (IC50=5 nM).
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-N0674
CAS No.: 30045-16-0
Synonyms: 13-Methylpalmatine
Dehydrocorydaline (13-Methylpalmatine) is an orally active alkaloid that inhibits acetylcholinesterase (AChE) (IC50 = 0.62 μM). Dehydrocorydaline inhibits synaptosomal reuptake of serotonin/dopamine/norepinephrine, the NLRP3 inflammasome, microglial activation, biofilm formation, and Plasmodium/Trypanosoma growth, and has pain-relieving effects. Dehydrocorydaline activates p38 MAPK/MyoD-driven myoblast differentiation, binds SPTA1 (Kd = 2.18 µM), inhibits aldose reductase, hOCT2/3, hPMAT, MEK/ERK, NF-κB/TRAF6, IRE1/PERK, SMAD2/3, and NR2B phosphorylation, and modulates Bcl-2/Bax, caspase-8/7, and PARP signaling. Dehydrocorydaline can be used in research on pain, breast cancer, melanoma, non-small cell lung cancer, bacterial infections, parasitic infections, pulmonary fibrosis, and atherosclerosis .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-N0674A
CAS No.: 10605-03-5
Synonyms: 13-Methylpalmatine chloride
Dehydrocorydaline (13-Methylpalmatine) chloride is an orally active alkaloid that inhibits acetylcholinesterase (AChE) (IC50 = 0.62 μM). Dehydrocorydaline chloride inhibits synaptosomal reuptake of serotonin/dopamine/norepinephrine, the NLRP3 inflammasome, microglial activation, biofilm formation, and Plasmodium/Trypanosoma growth, and has pain-relieving effects. Dehydrocorydaline chloride activates p38 MAPK/MyoD-driven myoblast differentiation, binds SPTA1 (Kd = 2.18 µM), inhibits aldose reductase, hOCT2/3, hPMAT, MEK/ERK, NF-κB/TRAF6, IRE1/PERK, SMAD2/3, and NR2B phosphorylation, and modulates Bcl-2/Bax, caspase-8/7, and PARP signaling. Dehydrocorydaline chloride can be used in research on pain, breast cancer, melanoma, non-small cell lung cancer, bacterial infections, parasitic infections, pulmonary fibrosis, and atherosclerosis .
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-N0674B
Synonyms: 13-Methylpalmatine (hydroxyl)
Dehydrocorydaline (13-Methylpalmatine) (hydroxyl) is an orally active alkaloid that inhibits acetylcholinesterase (AChE) (IC50 = 0.62 μM). Dehydrocorydaline (hydroxyl) inhibits synaptosomal reuptake of serotonin/dopamine/norepinephrine, the NLRP3 inflammasome, microglial activation, biofilm formation, and Plasmodium/Trypanosoma growth, and has pain-relieving effects. Dehydrocorydaline (hydroxyl) activates p38 MAPK/MyoD-driven myoblast differentiation, binds SPTA1 (Kd = 2.18 µM), inhibits aldose reductase, hOCT2/3, hPMAT, MEK/ERK, NF-κB/TRAF6, IRE1/PERK, SMAD2/3, and NR2B phosphorylation, and modulates Bcl-2/Bax, caspase-8/7, and PARP signaling. Dehydrocorydaline (hydroxyl) can be used in research on pain, breast cancer, melanoma, non-small cell lung cancer, bacterial infections, parasitic infections, pulmonary fibrosis, and atherosclerosis .
loading...
    loading...
45
45 Cited Publications
Cat. No.: HY-N4238
CAS No.: 13005-09-9
Synonyms: 13-Methylpalmatine nitrate
Dehydrocorydaline (13-Methylpalmatine) nitrate is an orally active alkaloid that inhibits acetylcholinesterase (AChE) (IC50 = 0.62 μM). Dehydrocorydaline nitrate inhibits synaptosomal reuptake of serotonin/dopamine/norepinephrine, the NLRP3 inflammasome, microglial activation, biofilm formation, and Plasmodium/Trypanosoma growth, and has pain-relieving effects. Dehydrocorydaline nitrate activates p38 MAPK/MyoD-driven myoblast differentiation, binds SPTA1 (Kd = 2.18 µM), inhibits aldose reductase, hOCT2/3, hPMAT, MEK/ERK, NF-κB/TRAF6, IRE1/PERK, SMAD2/3, and NR2B phosphorylation, and modulates Bcl-2/Bax, caspase-8/7, and PARP signaling. Dehydrocorydaline nitrate can be used in research on pain, breast cancer, melanoma, non-small cell lung cancer, bacterial infections, parasitic infections, pulmonary fibrosis, and atherosclerosis .
loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-119240
CAS No.: 324759-76-4
Purity:  99.05%
Target:  

PERK Autophagy

Research Areas:  

Neurological Disease Cancer

CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-100403
CAS No.: 298690-60-5
Purity:  99.67%
Target:  

mGluR

Research Areas:  

Cancer

Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-13032B
CAS No.: 1895049-20-3
Purity:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Research Areas:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
23
23 Cited Publications
Cat. No.: HY-148439
CAS No.: 2765081-21-6
Purity:  99.68%
Synonyms: RMC-6236; RAS-IN-2
Target:  

Ras PERK

Research Areas:  

Cancer

Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-12661A
CAS No.: 1883548-84-2
Purity:  99.67%
Target:  

PERK Autophagy

Research Areas:  

Cancer

AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC50 of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC50=7300 nM) and B-Raf (IC50 >1000 nM), respectively. AMG PERK 44 induces autophagy .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-14463
CAS No.: 912999-49-6
Purity:  99.92%
Synonyms: AT13387
Target:  

HSP

Research Areas:  

Cancer

Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-B0112
CAS No.: 38304-91-5
Synonyms: U10858
Minoxidil (U10858) is an orally active ATP-sensitive potassium channel opener and vasodilator. Minoxidil activates Wnt/β-catenin signaling pathway, increases ERK and Akt phosphorylation, upregulates Bcl-2 and downregulates Bax, thereby promoting dermal papilla cell proliferation and hair follicle elongation. Minoxidil downregulates IL-1α, inhibits T lymphocyte activity, reduces 5α-reductase expression, and attenuates the transcriptional activity of androgen receptor. Minoxidil is converted by hair follicle sulfotransferase to Minoxidil sulfate, shortening telogen and prolonging anagen. Minoxidil can be used in research related to hair loss .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-137207
CAS No.: 864388-65-8
Purity:  99.88%
Target:  

PERK

Research Areas:  

Neurological Disease

MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-13822
CAS No.: 312636-16-1
Purity:  99.25%
SKI-II is an orally active dual-target inhibitor of SphK1/2 and DES1, with Ki values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. In vivo, SKI-II inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway. SKI-II reduces measles virus replication by inhibiting mTORC1 activity. SKI-II binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-139612
CAS No.: 2653994-08-0
Purity:  98.71%
Synonyms: JDQ-443; NVP-JDQ443
Target:  

Ras PERK

Research Areas:  

Inflammation/Immunology Cancer

Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor. Opnurasib shows antitumor activity .
loading...
    loading...